FI4320112T3 - Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitä - Google Patents
Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitäInfo
- Publication number
- FI4320112T3 FI4320112T3 FIEP22718513.9T FI22718513T FI4320112T3 FI 4320112 T3 FI4320112 T3 FI 4320112T3 FI 22718513 T FI22718513 T FI 22718513T FI 4320112 T3 FI4320112 T3 FI 4320112T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- salt
- chf
- hydrogen
- oxoisoindoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4320112T3 true FI4320112T3 (fi) | 2025-07-25 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22718513.9T FI4320112T3 (fi) | 2021-04-06 | 2022-04-05 | Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitä |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11718601B2 (enExample) |
| EP (1) | EP4320112B1 (enExample) |
| JP (1) | JP7821197B2 (enExample) |
| KR (1) | KR20230165815A (enExample) |
| AR (1) | AR125298A1 (enExample) |
| AU (1) | AU2022253242A1 (enExample) |
| BR (1) | BR112023020077A2 (enExample) |
| CA (1) | CA3214244A1 (enExample) |
| CL (1) | CL2023002966A1 (enExample) |
| CO (1) | CO2023013321A2 (enExample) |
| DK (1) | DK4320112T3 (enExample) |
| ES (1) | ES3035755T3 (enExample) |
| FI (1) | FI4320112T3 (enExample) |
| HR (1) | HRP20250796T1 (enExample) |
| HU (1) | HUE072309T2 (enExample) |
| IL (1) | IL307343A (enExample) |
| LT (1) | LT4320112T (enExample) |
| MX (1) | MX2023011715A (enExample) |
| PE (1) | PE20231941A1 (enExample) |
| PL (1) | PL4320112T3 (enExample) |
| PT (1) | PT4320112T (enExample) |
| RS (1) | RS66982B1 (enExample) |
| SI (1) | SI4320112T1 (enExample) |
| SM (1) | SMT202500281T1 (enExample) |
| TW (1) | TWI867287B (enExample) |
| WO (1) | WO2022216644A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20240327381A1 (en) * | 2023-02-08 | 2024-10-03 | Celgene Corporation | Compounds and Compositions for Selective Degradation of Engineered Proteins |
| KR102834908B1 (ko) * | 2023-09-02 | 2025-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물 |
| WO2025199379A1 (en) | 2024-03-22 | 2025-09-25 | Bristol-Myers Squibb Company | Novel fak degrader compounds and uses thereof |
| WO2025226767A1 (en) * | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2025234887A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025234888A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| NZ531294A (en) | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| SG11201708303XA (en) | 2015-05-22 | 2017-11-29 | Biotheryx Inc | Compounds targeting proteins, compositions, methods, and uses thereof |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| BR112018068906A2 (pt) | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10865205B2 (en) | 2016-04-22 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CA3036834A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| EP3773576A4 (en) * | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019241271A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| WO2020102195A1 (en) * | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230093099A1 (en) | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 EP EP22718513.9A patent/EP4320112B1/en active Active
- 2022-04-05 ES ES22718513T patent/ES3035755T3/es active Active
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 SI SI202230144T patent/SI4320112T1/sl unknown
- 2022-04-05 PL PL22718513.9T patent/PL4320112T3/pl unknown
- 2022-04-05 DK DK22718513.9T patent/DK4320112T3/da active
- 2022-04-05 PT PT227185139T patent/PT4320112T/pt unknown
- 2022-04-05 MX MX2023011715A patent/MX2023011715A/es unknown
- 2022-04-05 HU HUE22718513A patent/HUE072309T2/hu unknown
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 LT LTEPPCT/US2022/023387T patent/LT4320112T/lt unknown
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko active Pending
- 2022-04-05 HR HRP20250796TT patent/HRP20250796T1/hr unknown
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
- 2022-04-05 JP JP2023561684A patent/JP7821197B2/ja active Active
- 2022-04-05 FI FIEP22718513.9T patent/FI4320112T3/fi active
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 TW TW111112957A patent/TWI867287B/zh active
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 SM SM20250281T patent/SMT202500281T1/it unknown
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en not_active Ceased
- 2022-04-05 RS RS20250660A patent/RS66982B1/sr unknown
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en not_active Abandoned
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
-
2024
- 2024-06-25 US US18/740,857 patent/US20240376082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230303527A1 (en) | 2023-09-28 |
| PT4320112T (pt) | 2025-07-07 |
| SI4320112T1 (sl) | 2025-09-30 |
| EP4320112A1 (en) | 2024-02-14 |
| US20220324840A1 (en) | 2022-10-13 |
| AR125298A1 (es) | 2023-07-05 |
| JP2024515243A (ja) | 2024-04-08 |
| PE20231941A1 (es) | 2023-12-05 |
| CO2023013321A2 (es) | 2023-10-19 |
| US20240376082A1 (en) | 2024-11-14 |
| EP4320112B1 (en) | 2025-05-14 |
| DK4320112T3 (da) | 2025-08-18 |
| LT4320112T (lt) | 2025-07-10 |
| AU2022253242A1 (en) | 2023-11-23 |
| SMT202500281T1 (it) | 2025-09-12 |
| TW202304881A (zh) | 2023-02-01 |
| CA3214244A1 (en) | 2022-10-13 |
| RS66982B1 (sr) | 2025-07-31 |
| BR112023020077A2 (pt) | 2023-11-14 |
| JP7821197B2 (ja) | 2026-02-26 |
| HRP20250796T1 (hr) | 2025-08-29 |
| PL4320112T3 (pl) | 2025-07-21 |
| ES3035755T3 (en) | 2025-09-08 |
| HUE072309T2 (hu) | 2025-11-28 |
| CL2023002966A1 (es) | 2024-02-23 |
| KR20230165815A (ko) | 2023-12-05 |
| WO2022216644A1 (en) | 2022-10-13 |
| MX2023011715A (es) | 2023-10-12 |
| US11718601B2 (en) | 2023-08-08 |
| IL307343A (en) | 2023-11-01 |
| TWI867287B (zh) | 2024-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4320112T3 (fi) | Pyridinyylisubstituoituja oksoisoindoliiniyhdisteitä | |
| JP2021504443A5 (enExample) | ||
| HRP20201146T1 (hr) | Spojevi indol karboksamida korisni kao inhibitori kinaze | |
| HRP20140279T1 (hr) | Antagonisti trpv1 i njihova uporaba | |
| AR094887A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| PE20141064A1 (es) | Compuestos de ester boronato y composciones farmaceuticas de los mismos | |
| RU2015102834A (ru) | Фунгицидные гетероциклические карбоксамиды | |
| JP2016536364A5 (enExample) | ||
| JP2015517495A5 (enExample) | ||
| RU2016122094A (ru) | Замещенные бензамиды для борьбы с членистоногими | |
| AR096902A1 (es) | Derivados de triazina y pirimidina como inhibidores de la idh1 y/o idh2 mutantes y su uso en el tratamiento del cáncer | |
| JP2010506825A5 (enExample) | ||
| PY1030698A (es) | Mezclas pesticidas mesoionicos | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| JO3809B1 (ar) | مركب (6S، 9aS)-N- بنزيل -6-[(4- هيدروكسي فينيل) ميثيل]-4، 7- داي أوكسو -8-({6-[3-(بيبرازين -1- يل) أزيتيدين -1- يل] بيريدين -2- يل} ميثيل)-2-(بروب-2-إين- 1- يل)- أوكتا هيدرو -1H- بيرازينو [2، 1-c][1، 2، 4] ترايازين -1- كربوكساميد | |
| JP2012532848A5 (enExample) | ||
| MEP22308A (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| BR112022024756A2 (pt) | Piridino de n-fenilaminocarbonila, pirimidino e benzo-tropanos como moduladores de gpr65 | |
| MX2022002362A (es) | Derivado de 2-aminoquinazolinona. | |
| AR119453A1 (es) | Derivados de piridazina | |
| HRP20231571T1 (hr) | Derivati fenil/piridil-nh-fenil/piridil za liječenje infekcija rna virusom | |
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| AR109950A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
| MX2013003227A (es) | Nuevos analogos de piperazina con grupos heteroarilo sustituidos como antivirales de la influenza de espectro amplio. | |
| ES527521A0 (es) | Un procedimiento para la preparacion de nuevos derivados de benzoxazolinona sustituidos |